Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.17 USD
Change Today +0.02 / 1.74%
Volume 238.8K
DSCO On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

discovery laboratories inc (DSCO) Snapshot

Open
$1.15
Previous Close
$1.15
Day High
$1.18
Day Low
$1.14
52 Week High
04/3/14 - $2.34
52 Week Low
12/9/14 - $0.99
Market Cap
100.1M
Average Volume 10 Days
669.1K
EPS TTM
$-0.51
Shares Outstanding
85.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DISCOVERY LABORATORIES INC (DSCO)

Related News

No related news articles were found.

discovery laboratories inc (DSCO) Related Businessweek News

No Related Businessweek News Found

discovery laboratories inc (DSCO) Details

Discovery Laboratories, Inc., a specialty biotechnology company, focuses on developing products for critical-care patients with respiratory disease and improving care in pulmonary medicine. Its proprietary drug technology produces a synthetic peptide-containing surfactant (KL4 surfactant in liquid, lyophilized, and aerosolized dosage forms), as well as develops drug delivery technologies to enable efficient delivery of its aerosolized KL4 surfactant. The company offers SURFAXIN Intratracheal suspension for the prevention of respiratory distress syndrome (RDS) in premature infants; AFECTAIR device, a disposable aerosol-conducting airway connector for infants; and WARMING CRADLE, a dry-block heating device that is designed to warm drug vials at the same temperature that is designated in the SURFAXIN prescribing information. It is also developing AEROSURF, a drug/device combination product that delivers KL4 surfactant in aerosolized form using the lyophilized KL4 surfactant is in Phase II clinical trials for the treatment of RDS in premature infants. In addition, the company is developing a lyophilized (freeze-dried) dosage form of its KL4 surfactant. The company has a collaboration agreement with Battelle Memorial Institute for the development and commercialization of AEROSURF; and a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain. Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

110 Employees
Last Reported Date: 03/16/15
Founded in 1992

discovery laboratories inc (DSCO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $493.3K
Chief Operating Officer and Senior Vice Presi...
Total Annual Compensation: $380.3K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $303.5K
Compensation as of Fiscal Year 2013.

discovery laboratories inc (DSCO) Key Developments

Discovery Laboratories, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Discovery Laboratories Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported a net loss of $10.6 million or $0.15 per diluted share compared to a net loss of $11.7 million or $0.16 per basic and diluted share for the same period a year ago. Operating loss was $11,226,000 compared to $10,265,000 last year. Net cash outflows for the quarter ended December 31, 2014 were $10.2 million. Total revenue was $1,184,000 compared to $74,000 last year. For the year, the company reported a net loss of $44,058,000 or $0.56 per diluted share compared to a net loss of $45,215,000 or $0.82 per basic and diluted share for the same period a year ago. Operating loss was $43,258,000 compared to $44,508,000 last year. Total revenue was $2,835,000 compared to $388,000 last year.

Discovery Laboratories Inc. to Report Q4, 2014 Results on Mar 17, 2015

Discovery Laboratories Inc. announced that they will report Q4, 2014 results at 12:30 PM, GMT Standard Time on Mar 17, 2015

Discovery Laboratories Inc., Q4 2014 Earnings Call, Mar 17, 2015

Discovery Laboratories Inc., Q4 2014 Earnings Call, Mar 17, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSCO:US $1.17 USD +0.02

DSCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $46.78 USD +0.28
View Industry Companies
 

Industry Analysis

DSCO

Industry Average

Valuation DSCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.2x
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DISCOVERY LABORATORIES INC, please visit www.discoverylabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.